MDLA Maintains Solid Performance, Q3 2025 Profit Grows Double Digits

Entering the second half of 2025, PT Medela Potentia Tbk (MDLA) continues to demonstrate its ability to sustain growth amid an increasingly competitive market. Through consistent business diversification and operational efficiency across its business lines, the Company posted double-digit profit growth through the third quarter of 2025.

During the first nine months of 2025, MDLA recorded revenue of IDR 11.1 trillion, an increase of 2.8% compared to the same period last year. Net profit rose significantly by 16.3% to IDR 294 billion, while gross profit grew 5.6% to IDR 1.07 trillion. The improved gross margin was driven by portfolio optimization and stronger contributions from key strategic principals.

President Director of PT Medela Potentia Tbk, Mr. Krestijanto Pandji, stated that this achievement reflects the effectiveness of MDLA’s continuous business diversification strategy.

“We continue to strengthen integration across subsidiaries and maintain operational efficiency to ensure sustainable and high-quality growth,” he said.

Robust growth also came from new initiatives across the Company’s core business lines. In the medical device manufacturing segment, subsidiary PT Deca Metric Medica (DMM) achieved a major milestone with its first export shipments to Timor-Leste and Cambodia, marking an important step toward regional market expansion.

In digital platforms, both B2B and B2C channels continued to deliver strong performance. The GPOS B2B platform recorded a 10% increase in sales with distribution coverage expanding by 22%. Meanwhile, GoApotik posted a 31% increase in revenue, supported by a 34% rise in customers and a 13% growth in transactions.

In the distribution segment, through subsidiary PT Anugrah Argon Medica (AAM), MDLA continued to strengthen strategic partnerships with the addition of four new principals by the end of the third quarter—comprising one consumer health category and three medical device categories. This further reinforces AAM’s position as a trusted distribution partner for both national and international pharmaceutical and medical device manufacturers.

Aligned with its sustainability commitment, MDLA also continues to enhance the implementation of Environmental, Social, and Governance (ESG) principles. The Company received recognition at the IDX Channel Anugerah ESG and earned two distinctions at the Top GRC Awards 2025: the TOP GRC #4 Star (Very Good) rating and The Most Committed GRC Leader 2025 award.

“These achievements reflect MDLA’s consistent efforts to build strong, resilient, and sustainability-oriented governance. We remain optimistic that this positive momentum will continue through the end of the year,” concluded Mr. Krestijanto Pandji.